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Abstract:   
 Anogeissus latifolia (Combretaceae) has been used in traditional system of medicine in India for over many years, and 
widely used to enhance the immune system and against various ailments. During the last decade many in-vitro, in-vivo 
and analytical studies witnessed and justified the traditional claim of this plant. The study was aimed to evaluate the 
preventive effect of Anogeissus latifolia bark in insulin resistance and metabolic dyslipidemia induced by high fructose 
diet feeding in rats. At the end of the treatment period, the plasma from normal control, diabetic, reference standard and 
Anogeissus latifolia extract (300mg/kg) treated animals were subjected to estimation of insulin, lipid profile, liver 
marker enzymes and kidney function test. Anogeissus latifolia was found to attenuate insulin resistance and metabolic 
dyslipidemia induced by adverse effects of fructose. This study validates the traditional use and shows a possible 
beneficial effect of the plant in the treatment of diabetes mellitus.  
Key Words: Anogeissus latifolia, High Fructose Diet, Insulin Resistance, Metabolic Disorder.  
1.  Introduction  
Type-2 diabetic condition is prevalent worldwide and is associated with morbidity and mortality, which are secondary 
to complications such as myocardial infraction, stroke and end stage renal disease (Se Na Yun et al, 2004). Nutritional 
or dietary oxidative stress denotes a disturbance of the redox state resulting from excess oxidative load or from 
inadequate nutrient supply favoring prooxidant reactions. Postprandial increases of lipid and carbohydrate levels lead 
to increased oxidative stress and lipid hydroperoxides present in the diet are absorbed, contributing to the prooxidant 
load (Helmut et al, 2005). Low intake or impaired availability of dietary antioxidants weakens the antioxidant network.  
Postprandial oxidative stress, as a sub form of nutritional oxidative stress, ensues from sustained postprandial 
hyperlipidemia and/or hyperglycemia and is associated with a higher risk for atherosclerosis, diabetes, and obesity 
(Tsai et al, 2004). Moreover, although data are scarcer, the fact that fructose may increase intrahepatic lipids and leads 
to insulin resistance in experimental settings raises some concern. In animal models, the potential danger of fructose 
consumption and its links to various metabolic disorders have been widely documented (Luc Tappy et al, 2009). 
Deleterious effects of high fructose intake on body weight, insulin sensitivity/glucose homeostasis, dyslipidemia, and 
atherosclerotic disease has been identified, and potential mechanisms have been proposed (Luc Tappy et al, 2009). 
High fructose consumption is suspected to be causally linked to the epidemics of obesity and metabolic disorders. A 
study by Nagai et al has focused a particular gene, known as PGC-1 beta, appears to play a key role in the development 
of insulin resistance in response to a high-fructose diet (Nagai et al, 2009).  Currently available pharmacological 
agents for type-2 diabetes have a number of limitations associated with high rate of secondary failure (Inzucchi et al, 
2002). In response to the enormity of the growing problem, efforts to identify and develop new pharmacological agents 
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for type-2 diabetes medicinal herbs with antihyperglycemic and antihyperlipidemic activities are increasingly sought 
by diabetic patients and health care professionals. Commonly used herbs and other alternative therapies, less likely to 
have the side effects of conventional approaches for type-2 diabetes, are reviewed. These efforts have resulted in the 
successful screening of medicinal herbs with antihyperglycemic activity (Lucy Deg et al, 2002). To date, over 400 
traditional plant treatments for diabetes have been reported (Bailey et al, 1989). The hypoglycemic effect of some 
herbal extracts has been confirmed in human and animal models of type 2 diabetes. The World Health Organization 
Expert Committee on diabetes has recommended that traditional medicinal herbs to be further investigated (Bailey et 
al, 1989). The current study was designed to investigate the antihyperlipidemic effect of Anogeissus latifolia bark in 
model of hypertriglyceridemia and insulin resistance induced by high fructose diet, which is considered as a good 
model for type-2 diabetes as it displays many of the characteristics of the human diseases including hyperglycemia, 
insulin resistance and progressive obesity (Hummel et al, 1966). 
Anogeissus latifolia, (A.latifolia) (Combretaceae), locally known as Dhava, is a moderate sized tree characteristic of 
dry deciduous forests and available throughout India. In phytotherapy, the bark, leaves, heartwood and roots of the 
plant is traditionally used for the treatment of dysentery, snakebite, leprosy, wounds and ulcers, skin diseases, jaundice 
and diabetes (Anonymous 1987). The bark is reported to have potent antioxidant activity (Govindarajan et al 2004a) 
and possess several biological activities like antiulcer, antimicrobial (Govindarajan et al 2006), wound healing 
(Govindarajan et al 2004b), chemo protective (Khan et al,2008), anthelmentic (Hemamalini et al,2011), 
nephroprotective (Veenavamshee et al,2011) and hepatoprotective (Pradeep et al,2009). The bark contains tannin and 
phenolic compounds (Gallic acid, ellagic acid, chebulic acid), flavonoids (rutin and quercetin)(Reddy et 
al,1965,Deshpande et al,1976), triterpenoids and phytosterol (β-sitosterol) (Mohammad et al,2007, Uday Sing et 
al,2011) which might contribute to various pharmacological activities. These constituents are reported to possess 
potential antioxidant activity and offer protection against various diseases (Aruoma et al, 1993, Festa et al, 2001, Boyle 
et al,2000, Boots et al,2008, Francisco et al,2009). Beneficial effects of A.latifolia and its gum exudates (commonly 
known as Gum gatti) have been evidenced in experimental diabetic animals in Streptozotocin- induced (Type-1) 
diabetic model (Parvathi et al,2009a) and in atherogenic diet induced hyperlipidemic model (Parvathi et al,2009b) 
respectively. These pharmacological evidences and rich antioxidant phytoconstituents of A.latifolia promoted us to 
explore the antihyperglycemic activity of A. latifolia bark extract in high fructose diet induced model of the metabolic 
syndrome in rats. 
2. Materials and Methods 
2.1 Composition of High Fructose Diet  
High fructose diet consisted of 60 % fructose. The 60 % fructose concentration was chosen because this amount 
produces hippocampal insulin resistance in hamsters (Mielkej al al, 2005), leads to peripheral pathology in rats similar 
to the pathology associated with fructose consumption in humans (Elliotl et al, 2002, Montonenj et al,2007), and is the 
amount used most extensively in rodent studies (Demoura et al,2008, Suga et al,2000). The control group was fed a diet 
of standard rat chow consist of 60 % vegetable starch ad libitum. Both diets contained equal percentages of 
carbohydrates (65 %), proteins (20 %), and lipids (10 %), and both diets were also isocaloric on a weight basis 
(kcal/gm) (Anonymous 1977). The control group received standard pellet chow for 6 weeks. 
 
Composition                          High Fructose Diet g/kg (kcal) 
Fructose                   600 (2208) 
Casein                            200(800) 
Corn oil                                                   100(900) 
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DL Methionine                                         3(12) 
Choline bitartrate                                       2(0) 
AIN-76 Mineral mix                                   35(0) 
AIN-76A vitamin mix                                10(40) 
Starch                                                      50(0) 
2.2 Plant Material 
Bark of A.latifolia was collected from Nallamala forest, Mahaboobnagar district, Andhra Pradesh, India, during the 
month of May. It was authenticated from Osmania University, Hyderabad. 
 2.3 Extraction of Plant Material 
The bark was shade dried and powdered coarsely. The coarse powder obtained was extracted exhaustively with 70% 
ethanol in Soxhlet apparatus and filtered. The extract was concentrated under reduced temperature and pressure to get 
dry residue and stored in a desiccators. 
2.4 Animals and Treatment Schedule 
Thirty male Wister rats, 6 weeks old and weighing roughly above 150 g, were procured from Mahaveer Enterprises and 
were housed in polypropylene cages in a temperature-controlled room (25
o
±2
o
C) with a 12 h light/12 h dark cycle. All 
rats were adapted and fed a standard pellet chow diet for 1 week. Rats had unrestricted access to food and water. Food 
intakes were monitored daily, and body weights were measured weekly. All rats were randomly divided into four 
groups (n = 6 each): Group I, normal control group: fed with a standard diet with normal saline daily using an intra 
gastric tube, Group II, diabetic control group: fed with HFD with normal saline daily using  an intragastric tube , 
Group III A. latifolia treated group: fed with HFD and A. latifolia (300 mg/kg body weight) in aqueous solution treated 
daily using an intra-gastric tube, and Group IV Rosiglitazone-treated group: fed with HFD and rosiglitazone (60 µg/kg 
body weight) in aqueous  solution treated daily using an intra-gastric tube for 6 weeks. The study protocol was 
approved by the Institutional Animal Ethics Committee (NIP/1330/AC/10/CPCSEA Dated 11
th
 March), Nizam 
Institute of Pharmacy, (Hyderabad, Andhra Pradesh, India) and the rats were maintained in accordance with the 
National Institute of Nutrition, Indian Council of Medical Research, Hyderabad, India guidelines for the care and use 
of laboratory animals. 
2.5 Oral Glucose Tolerance Test (OGTT) 
OGTTs were performed at weekly intervals during the experimental period. The rats were food deprived for 12 h prior 
to the administration of an oral glucose load (2 g/kg body weight, 200 g/ l solution). Blood samples were drawn from 
the tail vein at 0, 30, 60, and 90 min after glucose feeding. Glucose levels were determined using an Accu-Check 
Advantage Blood Glucose Monitor (Roche Group, Indianapolis, IN, USA). 
2.6 Blood and Tissue Collection 
At the end of study, blood samples were collected in a heparinized tube by puncturing the orbital venous plexus of 12-h 
fasted and anesthetized rats. Whole blood samples were centrifuged at 4500 rpm for 10 min at 4°C and plasma was 
separated out and stored at −70°C until further analysis. All the animals were sacrificed by cervical dislocation, liver, 
pancreas and   epididymal fat pad were removed and rinsed with chilled phosphate buffered saline (pH 7.0) and 
weighed. After immediate weighing, the liver tissues were chopped into small pieces and stored at −20°C until further 
use. 
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2.7 Blood and Liver Tissue 
2.7.1 Lipid Profile: Plasma total-cholesterol, Triglycerides (TG), and LDL cholesterol (LDL-C) were estimated by 
using enzymatic kits procured from E-Merck. 
2.7.2 Liver and Kidney Function Tests: The liver function tests (aspertate transaminase (AST), alanine transaminase 
(ALT), plasma Albumin/globulin ratio (A/G ratio), and total bilirubin) and kidney function tests (plasma urea and 
creatinine) were estimated using the E-Merck kits. 
2.7.3 Estimation of Plasma Insulin, Liver Glycogen Content and HMG CoA Reductase Activity 
 The plasma insulin was measured with an Autoanalyser (Auto lab 200) according to the manufacturer’s instructions 
(Merck,). 
Liver glycogen content was determined using the method reported by Van der Vies et al, 1954. Liver tissue (200 mg) 
was finely ground with 20 ml of 5% TCA in a homogenizer and protein precipitate was filtered. Clear filtrate (2 ml) 
was pipette out into a 20-ml calibrated test tube and then 10 N KOH (2 ml) was added. This tube was placed in a boiling 
water bath for 1 h. After cooling, 1 ml of glacial acetic acid was added to neutralize the excess of alkali and fluid 
brought up to the mark with water. Slowly, 2 ml of solution from the previous step was added to a test tube containing 
4 ml of anthrone reagent, which was placed in cold water to prevent excessive heating. After thorough mixing, the tube 
was placed in a boiling water bath for exactly 10 min for the development of colour and cooled with running tap water. 
The optical density was read within 2 h in a spectrophotometer (SPECORD 200; Analyjetika, Germany) at 650 nm 
against a blank that was prepared by subjecting 2 ml of 5% TCA instead of sample to the same procedure. Serum was 
used for the estimation of HMG CoA reductase activity. Activity of HMG CoA reductase was determined using the 
method of Rao and Ramakrishnan et al, 1975  by determining the ratio of HMG CoA to mevalonate. 
3. Statistical Analysis 
 Data are expressed as the mean ± SEM. The results of the study were subjected to analysis of variance (ANOVA) 
using graph pad prism followed by Dunnett’s t-test for multiple comparisions.  P value <0.05 was considered 
statistically significant. 
4. Results 
4.1 Oral Glucose Tolerance Test (OGTT) 
 The results of glucose intolerance induced by high-fructose diet and comparative delaying effect of A.latifolia as well 
as rosiglitazone in rats during 6 weeks of the experimental period. In Glucose Tolerance Test, the Glucose levels were 
estimated before drug treatment and at different intervals thereafter. In the control group the blood glucose was found 
to increase linearly from basal value of 101.4 mg/dl to 191.8 mg/dl in the first 30 minutes. After 60 minutes of glucose 
loading, the blood glucose was increased further. The maximum value of 312 mg/dl was seen at the 90th minute. 
Whereas in the extract treated animals, only a little elevation in the blood glucose were seen from basal value of 97.4 
mg/dl to 113.8 mg/dl in the first 30 minutes, 78.2 mg/dl in the 90 minutes and 89.4mg/dl at 150 minutes and maximum 
glucose tolerance was observed at 90
th
 minute. In rosiglitazone treated animals blood glucose rises to 106 mg/dl from 
basal value of 93.3 mg/dl in the first 30 minute, 72.4 mg/dl in 90 minutes and 79.6 mg/dl at 150 minutes and maximum 
glucose tolerance was observed at 90
th
 minute.  
4.2 Effect on Body, liver and Pancreas Weight  
Table 1 shows the values of body weight, weight of liver, pancreatic tissue and epididymal fat of normal and diabetic 
animals and the comparative effect of A.latifolia as well as rosiglitazone in HFD-fed rats. The body weight and 
epididymal fat of the diabetic control animals was significant higher than those of all the other groups; however, 
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significant decrease was observed in body weight and epididymal fat content in A.latifolia and rosiglitazone-treated 
animals in comparison to the normal animals. The weights of liver and pancreatic tissue among all the groups were 
nearly similar.  
4.3 Effect on Hyperglycemia, Plasma Insulin, Liver Glycogen and HMG-CoA Reductase Activity 
 Administration of A.latifolia showed a significant antihyperglycemic activity in HFD-fed rats similar to standard 
rosiglitazone. The results in Table 2 and 3 show that blood glucose level, plasma insulin and liver glycogen in the 
diabetic control group were significant higher than those in the normal group (P<0.05). The levels of blood glucose 
level, plasma insulin and liver glycogen content were significantly lower in the A.latifolia treated animals than those of 
the diabetic control group (P<0.05) Similarly, rosiglitazone- treated animals also showed significantly lower values of 
blood glucose, plasma insulin and liver glycogen content as compared with the diabetic control group of animals 
(P<0.05). Diabetic rats exhibited a highly significant increase in liver HMG-CoA reductase activity as compared with 
the non-diabetic group. Administration of both A.latifolia and reference standard led to marked amelioration of 
HMG-CoA reductase activity. 
4.4 Effect on Plasma Lipid Levels 
 The changes in plasma lipid levels in the diabetic control, A.latifolia treated and rosiglitazone treated groups are 
summarized in Table 4. It demonstrates that the plasma total cholesterol, TG and LDL-C were significantly higher in 
the diabetic control animals than that in the normal animals. However, these variables were significantly lower in the 
A.latifolia treated rats than diabetic control rats (P<0.05). However, these values were almost similar to those of 
rosiglitazone-treated animals (P<0.05). In rosiglitazone-treated rats, plasma total cholesterol, TG and LDL-C, were 
also lower than those of diabetic control animals (P<0.05).  
4.5 Effect on Liver and Kidney Function Tests 
HFD fed rats showed significant increase in AST, ALT and Total bilirubin level and decrease in albumin/globulin ratio 
compared to rats fed standard diet indicating liver dysfunction. The oral administration of A.latifolia as well as 
rosiglitazone showed significant improvement in the liver function tests as compared to the parameters in diabetic 
control animals. However there was no significant variability observed in the kidney function tests of HFD, standard 
fed, A.latifolia and rosiglitazone treated animals (Table 5).  
5. Discussion  
Fructose is a potent reducing sugar that promotes the formation of toxic advanced glycation end-products, which 
appear to play a role in the aging process; in the pathogenesis of the vascular, renal, and ocular complications of 
diabetes; and in the development of atherosclerosis. In addition, excessive fructose consumption may be responsible in 
part for the increasing prevalence of obesity, diabetes mellitus, and non-alcoholic fatty liver disease characterized by 
an impaired glucose tolerance test. With a few exceptions, the relatively small amounts of fructose that occur naturally 
in fruits and vegetables are unlikely to have deleterious effects (Alan et al,2005). Study results revealed that treatment 
of diabetic rats with A. latifolia lead to significant amelioration of glucose tolerance. A decrease in elevated glucose 
levels is in agreement with the results of Vessal et al, 2003 and Kamalakkannan et al, 2006 who demonstrated 
similar effects of flavonoid, rutin in diabetic rats and also with those reported by Nuraliev et al, 1992 on a 
hypoglycemic effect of quercetin in diabetic animals. Thus, the hypoglycemic effect of A. latifolia may be due to the 
presence of flavonoids such as rutin and quercetin present in bark extract. Administration of A.latifolia and 
rosiglitazone delayed the appearance of an impaired glucose tolerance test. This beneficial effect shown for glucose 
absorption is postulated to be attributed to the activity of specific constituents, flavonoids in the A. latifolia, such as 
quercetin, which is recognized as an inhibitor of glucose absorption (Kwon et al, 2007). In addition, the other 
antioxidant constituents (Gallic acid, ellagic acid, sterols) of the A. latifolia may have also played a role in its effects. 
The results of present study showed that administration of A.latifolia to rats for six weeks inhibited the disturbance in 
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glucose metabolism in the liver by reducing the accumulation of glycogen in liver, which might be due to induced 
glycogenolysis and/or inhibited gluconeogenesis.  
Obese and type-2 diabetes are characterized by adipose tissue over production of pro inflammatory cytokines. The 
reduced body and epididymal fat weight in A.latifolia supplemented rats is probably due to reduced portal collagen 
deposition and fat deposition in the liver. Fructose-induced insulin resistant states are commonly characterized by a 
profound metabolic dyslipidemia, which appears to result from hepatic and intestinal overproduction of atherogenic 
lipoprotein particles. A high flux of fructose to the liver, perturbs glucose metabolism and glucose uptake pathways, 
and leads to a significantly enhanced rate of lipogenesis and triglyceride synthesis, resulting in high flux of glycerol 
and acyl portions of triglyceride molecules from fructose catabolism. These metabolic disturbances appear to underlie 
the induction of insulin resistance commonly observed with high fructose feeding in both humans and animal models 
(Heathe et al, 2005). The ability of A.latifolia to reduce plasma cholesterol and triglycerides in diabetic animals could 
be explained by the insulin releasing capacity of flavonoid constituents (Quercetin & Rutin) present in the bark 
extract (Hii et al, 1985). The hypolipidemic activity of A.latifolia may also be mediated, at least in part, via 
inactivation of hepatic HMG-CoA reductase, a key enzyme, in cholesterol synthesis. The observed activity may be 
due to flavonoids, rutin, quercetin of the extract which are reported to possess HMG-CoA reductase inhibiting 
activity (Bok et al, 2002, Osama et al, 2010). In concurrence with this attribution, Raz et al, 2005 state that inhibitors 
of hepatic HMG-CoA reductase are well established drugs for the treatment of hypercholesterolemia and decrease 
the incidence of dyslipidemia in diabetic subjects. This also coincides well with the work of Jung et al, 2006 who 
state that flavonoids decrease liver HMG-CoA reductase activity in type 2 diabetic mice. Moreover, rutin has been 
reported to lower hepatic and blood cholesterol levels, as stated by Park et al, 2002. It can be concluded that the 
ameliorative effect of A.latifolia extract on serum lipid variables may be attributed to their insulin releasing capacity 
and insulin binding affinity and decreasing intestinal cholesterol absorption and activity of hepatic HMG-CoA 
reductase. Hepatic damage in fructose-fed rats was evident from the increased plasma transaminase (Hult et al, 1986), 
as well as the decline in hepatic function from the elevated bilirubin level and the decreased A/G ratio. Increased 
aspartate transaminase (AST) activity is considered as markers of increased metabolic activity (Lottja et al, 1980). This 
biochemical changes reflect hepatocellular damage in fructose-fed rats. Fructose is known to induce renal hypertrophy 
and tubulointerstitial disease in rats (Nakayama et al, 2010, Kang et al, 1977). Reduction in AST activity therefore 
suggests decreased metabolic activity in A.latifolia administered rats. Moreover drug being Hepatoprotective may also 
have a role in attenuating hepatic changes brought about by high fructose feeding. The kidney function tests were 
screened based on the reports of Nakayama et al, 2010 and Kang et al, 1977. However there was no significant 
variability observed in the kidney function tests in HFD feeding, may be due to the shorter duration of the experiment. 
Further works on these aspects are expected to reveal the reason for discrepancies. Above results demonstrates the 
regenerative antioxidant effect of Anogeissus latifolia during progression of diabetes induced by metabolic changes in 
fructose fed rats. Although the antioxidant and free radical scavenging properties of A.latifolia and its constituents have 
been previously described (Govindarajan et al,2004a), this is the first study to our knowledge that demonstrates the 
preventive role of A.latifolia in high fructose diet induced dyslipidemia in rats. Phenolic compounds along with 
flavonoids as both insulin potentiating factors and antioxidants are postulated to act in preventing the metabolic 
syndrome, which is characterized by insulin resistance, dyslipidemia, and increased oxidative stress.  
6. Conclusion: The findings of the present study are of merit in revealing that A.latifolia possesses the potential 
to reverse the dyslipidemia caused by metabolic changes induced by high fructose diet in rats. This study 
validates the traditional use and shows a possible beneficial effect of the plant in the treatment of diabetes 
mellitus.  
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Table 1: Effect of A.latifolia on Body, Liver and Pancreas Weight. 
 
 
Parameters Normal HFD Control A. latifolia-Treated Rosiglitazone-Treated 
Initial Body Weight (g) 178.60±5.7 180.19±3.32 180.10±3.9 189.75±5.1 
Body weight gain (g) 13.30±4.5 15.38±5.0 
a
 11.89±10.11
a
 11.38±4.98
a
 
Liver weight (g) 7.49±2.56 7.11±2.10 7.54±2.0 7.38±3.4 
Pancreas 0.375±0.04 0.38±0.01 0.350±0.02 0.371±0.02 
Epididymal Fat 
(mg/100g) 
368.80 ± 67.20 451.20 ±58.29
abc
 378.30 ± 44.38
a
 387.20 ± 37.38
a
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The values are means ± S.E.M. of 6 animals in each group during and/ or after 48 days of the experimental period. 
Values quoted with a, in comparison to normal control group (P<0.05); b, in comparison to the A. latifolia-treated 
group (P<0.05); and c, in comparison to the rosiglitazone-treated group are significantly different (P<0.05). 
 
Table 2: Effect of A. latifolia on Blood Glucose Levels (mg/dl) on High Fructose Diet Induced Diabetic Rats after 
Repeated Doses. 
Groups Day 1 Day 12 Day 24 Day 36 Day 48 
Normal 71.66±1.30 73.4±2.0 77.83±1.72 83.16±1.75 82±1.06 
HFD  Control 282.50±1.76 278±1.18 286±1.42 294.14±1.49 302.27±1.52 
A.latifolia-Treated
 
307.83±1.84 138.16±2.29**
a
 114.83±2.16**
a
 110±2.25**
a
 96±2.23**
a
 
Rosiglitazone-Treated 291.68±1.04
b
 82.33±3.56
**b
 84.03±1.36
**b
 74.74±1.05
**b
 72.17±2.2
**b
 
 
Significance compared within the groups as follows: a. A. latifolia treated rats Vs. diabetic control rats.  
b. Rosiglitazone treated rats vs. diabetic control rats. Values are given as mean ± SEM for groups of six animals in each 
group. Values are statistically significant at *p<0.05 and **p<0.01. 
 
 
 
Table 3: Effect of A.latifolia and Rosiglitazone Treatment on Plasma Insulin, Liver Glycogen Content and 
HMG-CoA Reductase Activity after 6 weeks of Drug Treatment. 
 
Parameters Normal HFD Control A.latifolia Treated Rosiglitazone-Treated 
Plasma Insulin (U/ml) 238.3± 11.20 465.2 ± 24.12
a
 321.8 ± 18.58
abc
 309.9 ± 30.17
ab
 
Liver Glycogen 
Content          (mg/ 
g of liver tissue) 
 
6.91 ± 1.85 11.05 ± 1.58
a
 8.55 ± 2.0
abc
 7 .58 ± 3.0
ab
 
 
HMG- CoA Reductase
 1.13± 0.53 1.43± 0.74 1.32± 0.74
abc
 1.26± 0.02
abc 
 
The values are means ± S.E.M. of 6 animals in each group and significantly different (P<0.05): a, in comparison to the 
normal group; b, in comparison to the diabetic control group; and c, in comparison to the rosiglitazone-treated group. 
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Table 4: Effect of A. latifolia and Rosiglitazone Treatment on Plasma Lipid Levels after 6- weeks of Drug 
Treatment. 
 
Parameters Normal HFD Control A.latifolia -Treated Rosiglitazone-Treated 
Total Cholesterol(mg/dl) 
 
72.18 ± 7.09 118.30 ± 16.19
a
 97.38 ± 7.32
abc
 93.93 ± 10.2
ab
 
 
Triglyceride (mg/dl) 59.20 ± 4.33 86.15 ± 2.89
a
 73.29 ± 8.00
abc
 68.39 ± 3.98
ab
 
 
LDL-Cholesterol(mg/dl) 40.11 ± 3.81 70 .06 ± 12.0
a
 51.0 ± 3.53
abc
 48.91 ± 8.30
a
 
 
The values are means ± S.E.M. of 6 animals in each group and significantly different (P<0.05): a, in comparison to the 
normal group; b, in comparison to the diabetic control group; and c, in comparison to the rosiglitazone-treated group. 
 
Table 5: Effect of A.latifolia and Rosiglitazone Treatment on Liver and Kidney Function Tests after 6 Weeks. 
 
Parameters Normal HFD Control A.latifolia-Treated Rosiglitazone-Treated 
Liver Tests  
AST(IU/L) 75.6±4.4 168.3±6.8
a
 118.7±1.1
abc
 127. 5±5.6
b 
ALT(IU/L) 72.1±3.4 150.4±8.1
a
 109.4±4.5
abc
 119.6±5.3
b
 
A/G Ratio (mg/dl) 1.5±1.1 0.8±0.04
a
 1.2±4.9
abc
 1.3±3.2
b 
Total bilirubin(mg/dl) 0.5±0.04 1.02±0.06
a
 0.9±0.03
abc
 0.7±0.05
b
 
Kidney Function 
Tests 
Urea (mg/dl) 
14.92 ± 3.25 15.20 ± 4.0 15.30 ± 4.51 14.76 ± 4.56 
Creatinine(mg/dl) 0.84 ± 0.11 0.91 ± 0.18 0.92 ± 0.11 0.88 ± 0.08 
 
 
The values are means ± S.E.M. of 6 animals in each group and significantly different (P<0.05): a, in comparison to the 
normal group; b, in comparison to the diabetic control group; and c, in comparison to the rosiglitazone-treated group. 
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